These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6973945)

  • 21. Effects of alpha 1-acid glycoprotein on ristocetin, thrombin and Polybrene induced platelet aggregation.
    Coller BS
    Thromb Res; 1980 May 1-15; 18(3-4):579-84. PubMed ID: 6774438
    [No Abstract]   [Full Text] [Related]  

  • 22. [Determination of activity of ristocetin cofactor in blood using the coagulation time meter KZM-1].
    Lutze G; Töpfer G; Urbahn H
    Z Med Lab Diagn; 1983; 24(3):139-48. PubMed ID: 6604377
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of venom coagglutinin and lyophilized platelets in testing for platelet-aggregating von Willebrand factor.
    Brinkhous KM; Read MS
    Blood; 1980 Mar; 55(3):517-20. PubMed ID: 6965594
    [No Abstract]   [Full Text] [Related]  

  • 24. Abnormal polybrene-induced platelet agglutination in von Willebrand's disease.
    Rosborough TK; Swaim WR
    Thromb Res; 1978 May; 12(5):937-42. PubMed ID: 307834
    [No Abstract]   [Full Text] [Related]  

  • 25. Proceedings: Purification of ristocetin Willebrand factor (RWF).
    Olson JD; Fass DN; Brockway WJ; Bowie EJ; Mann KG
    Thromb Diath Haemorrh; 1975 Nov; 34(2):606. PubMed ID: 1081753
    [No Abstract]   [Full Text] [Related]  

  • 26. The nature of the interaction between ristocetin-Willebrand factor VIII coagulant activity molecule.
    Brockway WJ; Fass DN
    J Lab Clin Med; 1977 Jun; 89(6):1295-1305. PubMed ID: 16975
    [No Abstract]   [Full Text] [Related]  

  • 27. Interactions of purified rat factor VIII/von Willebrand factor with rat and human platelets--effect of albumin and ristocetin.
    Dejana E; Furlan M; Barbieri B; Donati MB; Beck EA
    Thromb Haemost; 1984 Aug; 52(1):57-9. PubMed ID: 6437011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.
    Ruggeri ZM; Pareti FI; Mannucci PM; Ciavarella N; Zimmerman TS
    N Engl J Med; 1980 May; 302(19):1047-51. PubMed ID: 6767976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolated recombinant domain of von Willebrand factor displaying increased sensitivity to ristocetin.
    Hayashi T; Ware J; Niiya K; Sakuragawa N
    Am J Hematol; 1996 Aug; 52(4):248-53. PubMed ID: 8701941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variant forms of von Willebrand's disease: type IIA, type IIB and platelet-type von Willebrand's disease.
    Takahashi H
    Nihon Ketsueki Gakkai Zasshi; 1984 Dec; 47(8):1678-89. PubMed ID: 6335811
    [No Abstract]   [Full Text] [Related]  

  • 31. Ristocetin in the diagnosis of von willebrand's disease: a comparison of rate and percent of aggregation with levels of the plasma factor(s) necessary for ristocetin aggregation.
    Dowling SV; Muntz RH; D'Souza S; Ekert H
    Thromb Diath Haemorrh; 1975 Nov; 34(2):465-74. PubMed ID: 1081746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identity of bovine platelet aggregation factor and ristocetin-Willebrand factor.
    Kalogjera V; Owen WG
    Thromb Res; 1978 Nov; 13(5):857-64. PubMed ID: 311087
    [No Abstract]   [Full Text] [Related]  

  • 33. Proceedings: Relationship between factor VIII and von Willebrand's factor in plasma and serum.
    Koutts J; Gude N; Firkin B
    Thromb Diath Haemorrh; 1975 Nov; 34(2):607. PubMed ID: 1081756
    [No Abstract]   [Full Text] [Related]  

  • 34. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers.
    Weiss HJ; Meyer D; Rabinowitz R; Pietu G; Girma JP; Vicic WJ; Rogers J
    N Engl J Med; 1982 Feb; 306(6):326-33. PubMed ID: 6798442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet-binding of the von Willebrand factor.
    Green D; Muller HP
    Thromb Haemost; 1978 Jun; 39(3):689-94. PubMed ID: 309191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Membrane fluidity and platelet aggregation: dibucaine permits ristocetin-induced platelet aggregation with low-molecular-weight von Willebrand multimers.
    Gjønnaess E; Solum NO; Brosstad F
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):395-405. PubMed ID: 1420815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of factor VIII-von Willebrand factor ristocetin cofactor activity by monoclonal antibodies.
    Hornsey V; Micklem LR; McCann MC; James K; Dawes J; McClelland DB; Prowse CV
    Thromb Haemost; 1985 Aug; 54(2):510-4. PubMed ID: 3878608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Letter: A method for assaying von Willebrand factor (ristocetin cofactor).
    Macfarlane DE; Stibbe J; Kirby EP; Zucker MB; Grant RA; McPherson J
    Thromb Diath Haemorrh; 1975 Sep; 34(1):306-8. PubMed ID: 1081281
    [No Abstract]   [Full Text] [Related]  

  • 39. ADP-induced inhibition of von Willebrand factor-mediated platelet agglutination.
    Grant RA; Zucker MB; McPherson J
    Am J Physiol; 1976 May; 230(5):1406-10. PubMed ID: 818909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative study of the effect of modification of the surface of human platelets on the receptors for aggregated immunoglobulins and for ristocentin-von Willebrand factor.
    Pfueller SL; Jenkins CS; Lüscher EF
    Biochim Biophys Acta; 1977 Mar; 465(3):614-26. PubMed ID: 319830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.